Trending GLP-1 Therapies Research Papers

yesterday • Frontiers in endocrinology

Semaglutide's effectiveness and safety for weight loss and excessive hunger in adults with Prader-Willi syndromeEfficacy and safety of semaglutide for obesity and hyperphagia in adults with Prader-Willi syndrome.

🎖️ Top 10% JournalObservational Study

1 week ago • PeerJ

Weight gain after stopping diabetes-related hormone treatments in overweight or obese adults: a review and analysisWeight regain following discontinuation of glucagon-like peptide-1 receptor agonists in adults who are overweight or obese: a systematic review and meta-analysis.

📖 Top 30% JournalFulltext (Open License)Systematic Review

yesterday • Frontiers in pharmacology

Risk of tumors with semaglutide treatment in people with type 2 diabetes: a review and combined analysis of clinical trialsRisk of neoplasms with semaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.

📖 Top 20% JournalSystematic Review

3 days ago • Endocrinology, diabetes & metabolism

Comparing the Effects of Semaglutide, Liraglutide, and Tirzepatide on Heart and Metabolic HealthImpact of Semaglutide, Liraglutide and Tirzepatide on Cardiometabolic Outcomes: A Comparative Narrative Review.

📖 Top 20% JournalComparative Study

3 days ago • BMC endocrine disorders

Effectiveness and safety of 12 mg versus 36 mg orforglipron doses for maintaining weight in people with obesity, with or without diabetesEfficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysis.

📖 Top 20% JournalSystematic Review

4 days ago • Frontiers in endocrinology

Changes in blood sugar control and weight in obese and non-obese adults with type 2 diabetes treated with SGLT-2 inhibitors or GLP-1 receptor agonistsComparative change in HbA1c and weight outcomes between obese and non-obese adults with type 2 diabetes mellitus treated with SGLT-2 inhibitors or GLP-1 receptor agonists.

🎖️ Top 10% JournalMulticenter Study

3 days ago • Frontiers in endocrinology

Added benefits of SGLT2 inhibitors, GLP-1 receptor agonists, and pioglitazone for type 2 diabetes and fatty liver disease in Asian populationsIncremental effects of SGLT2 inhibitors, GLP-1 receptor agonists, and pioglitazone in type 2 diabetes and MASLD across Asian study settings: a systematic review and meta-analysis.

🎖️ Top 10% JournalSystematic Review

1 week ago • Frontiers in public health

Cost-effectiveness of loxenatide compared to DPP-4 inhibitors for Chinese people with type 2 diabetes and high heart disease riskCost-utility analysis of loxenatide versus DPP-4 inhibitors in Chinese patients with type 2 diabetes at high cardiovascular risk.

📖 Top 20% JournalFulltext (Open License)Comparative Study

6 days ago • Clinical obesity

Differences in Weight Loss and Influencing Factors of GLP-1 Receptor Agonists and Dual Agonists in People with Obesity: A Meta-AnalysisWeight Reduction Heterogenicity and Mediators of GLP-1RAs and Dual Agonists for Individuals With Obesity: A Meta-Analysis.

📖 Top 30% JournalMeta-Analysis

4 days ago • Journal of clinical medicine

How GLP-1 Medicines Affect Body Fat and Muscle in People with Overweight and ObesityThe Impact of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists on Body Composition in Individuals with Overweight and Obesity: A Systematic Review and Meta-Analysis.

📖 Top 20% JournalArticle

1 week ago • Frontiers in pharmacology

Oral small-molecule drugs that activate GLP-1 receptors: a new approach in heart and metabolism healthOral small-molecule GLP-1 receptor agonists: a new Frontier in cardiometabolic medicine.

📖 Top 20% JournalFulltext (Open License)Article

2 days ago • Diabetologia

GPCRVP score reliably predicts how human GLP1R variants affect receptor functionThe GPCRVP score reliably predicts the impact of GLP1R human variants on receptor function.

🥈 Top 2% JournalArticle

4 days ago • Medicine

Health outcomes linked to GLP-1 receptor agonist use in fatty liver disease with metabolism problems: A multinational studyClinical outcomes associated with GLP-1 receptor agonist use in metabolic dysfunction-associated steatohepatitis: A multinational cohort study.

📖 Top 50% JournalMulticenter Study

2 days ago • Advances in nutrition (Bethesda, Md.)

Epigenetic Memory May Explain Weight Regain After Incretin TreatmentThe Incretin Mirage: Epigenetic Memory as a Potential Driver of Post-Treatment Weight Regain.

🥉 Top 5% JournalArticle

yesterday • British journal of clinical pharmacology

Using GLP-1 and related drugs to treat heart, liver, and metabolism problems in fatty liver diseaseTargeting the cardiohepatic-metabolic axis: GLP-1-based and incretin multi-agonist therapies in MASH.

📖 Top 20% JournalArticle

4 days ago • Nutrients

Hidden Malnutrition in the GLP-1 Treatment Era: Micronutrient Levels, Protein Intake, and Muscle Mass as Important Nutritional FactorsHidden Malnutrition in the GLP-1 Era: Micronutrient Status, Protein Adequacy, and Lean Mass as Emerging Nutritional Considerations-A Narrative Review.

🎖️ Top 10% JournalArticle

4 days ago • The Journal of clinical investigation

A specific brainstem circuit controls the unpleasant and appetite-reducing effects of GLP1R activatorsA single dorsal vagal complex circuit mediates the aversive and anorectic responses to GLP1R agonists.

🥈 Top 2% JournalArticle

4 days ago • Cells

🎖️ Top 10% JournalArticle

1 week ago • Drugs

Effects of GLP-1 Receptor Agonists on Muscle and Bone Health: A Review and AnalysisGLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis.

🥈 Top 2% JournalSystematic Review

2 days ago • BMJ open

Semaglutide as an additional treatment for obesity in teens taking antipsychotic drugs: plan for a first feasibility studySemaglutide as adjunct treatment for obesity in adolescents receiving antipsychotic medication (the GOAL trial): protocol for a single-arm, open-label feasibility study.

📖 Top 20% JournalClinical Trial Protocol

2 days ago • Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition

How a GLP-1 receptor activator may influence food intakeEffect of GLP-1 receptor agonist on nutrient intake: A narrative review.

📖 Top 30% JournalArticle

yesterday • Diabetology & metabolic syndrome

Effects of GLP-1 and GLP-1/GIP receptor drugs before, during, and after pregnancyImpact of GLP-1 and GLP-1/GIP receptor agonists before, during, and after pregnancy: a narrative review.

📖 Top 20% JournalArticle

4 days ago • Nutrients

Using Lifestyle Changes with Incretin-Based Weight Loss Drugs: Combining Exercise, Diet, and Behavior for Lasting ResultsLifestyle Medicine as Co-Therapy During Incretin-Based Anti-Obesity Pharmacotherapy: Integrating Physical Activity, Nutrition, and Behavioral Strategies for Long-Term Success.

🎖️ Top 10% JournalArticle

4 days ago • Biological psychiatry global open science

Drugs Targeting GLP-1 and GIP/GLP-1 Receptors for Alcohol Use, Obesity, and Heart-Related Metabolism ProblemsGLP-1 Receptor Agonist and GIP/GLP-1 Receptor Dual Agonist Therapeutics at the Intersection of Alcohol Use Disorder, Obesity, and Cardiometabolic Dysfunction.

🎖️ Top 10% JournalArticle

yesterday • PloS one

Different effects of semaglutide and CRV431 combined treatment on liver scarring and liver cancer in a fatty liver disease mouse modelDivergent effects of semaglutide and CRV431 Co-therapy on liver fibrosis and HCC in MASLD mouse model.

📖 Top 30% JournalArticle

3 days ago • JAMA cardiology

Semaglutide’s effectiveness and safety in people with different levels of frailtyEfficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical Trial.

🥇 Top 1% JournalArticle

3 days ago • Anaesthesia

Use of glucagon-like peptide-1 receptor drugs around surgery and patient outcomes in a national studyPeri-operative glucagon-like peptide-1 receptor agonist use and outcomes: a national prospective multicentre cohort study.

🥉 Top 5% JournalArticle

3 days ago • Mayo Clinic proceedings. Digital health

Body Weight and Blood Pressure Changes After Starting a Glucagon-Like Peptide 1 Drug: Analysis Using Data from Linked DevicesReal-World Body Composition and Blood Pressure Changes Following Glucagon-Like Peptide 1 Receptor Agonist Initiation: A Causal Inference Study of Connected Device Data.

📖 Top 50% JournalArticle

6 days ago • Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation

GLP-1 receptor drugs and their effects on body weight and heart healthEffects of GLP-1 receptor agonists on body weight and cardiovascular outcomes: a review.

📖 Top 30% JournalArticle

2 days ago • Childhood obesity (Print)

Nutritional Deficiencies, Health Issues, and Diet Support in Children Taking GLP-1 MedicinesNutritional Deficiencies, Complications, and Nutrition Therapy/Counseling in Pediatric Patients Using GLP-1 Receptor Agonists.

📖 Top 30% JournalArticle